Despite the pandemic and industry challenges, Lannett made significant progress on strategic initiatives. Key achievements include refinancing debt, extending debt maturity to 2026, and improving free cash flow by $50 million annually. Additionally, Lannett filed an ANDA for generic ADVAIR DISKUS, which is expected to launch in 2022, potentially generating substantial sales. The company also announced the potential launch of a generic Flovent product in 2023 and an insulin biosimilar in 2023. Insulin aspart biosimilar development is progressing, with potential launch in 2024. Lannett's balance sheet improved, with cash and cash equivalents increasing to $81 million, and the company maintained operating discipline, remaining on track to achieve near-term goals.